Cerebral Malaria Program
Cerebral malaria kills over 300,000 children a year in Africa and ‘scientists have confirmed that malaria parasites in Africa have developed resistance to a key family of drugs used to protect against them.’ Nature, Sept 2021.
Novapep’s Professor Mosnier co-authored a review paper demonstrating why APC, which should be an effective therapy in cerebral malaria, does not work. The malaria parasite produces a protein which blocks APC’s activity https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3888284/
The malaria parasite blocks the action of APC, but it cannot block G10’s mechanisms of action.
Novapep is developing a systemic form of G10 and Professor Mosnier is leading the G10 in cerebral malaria development activity.
Total funding for malaria control and elimination reached an estimated US$3 billion in 2019. Contributions from governments of endemic countries amounted to US$900 million, representing 31% of total funding. The WHO African Region carries a disproportionately high share of the global malaria burden. In 2019, the region was home to 94% of malaria cases and deaths. Pricing of systemic G10 will have modest margin over costs of goods to ensure the drug can be provided to all those in need.